What Is Sapropterin and Its Main Role?
Sapropterin, also known as tetrahydrobiopterin (BH4) or sold as Kuvan, is a synthetic form of BH4. It acts directly as a cofactor for phenylalanine hydroxylase (PAH), the enzyme that converts phenylalanine to tyrosine in the liver. Rather than regulating the creation of cofactors, sapropterin is the cofactor itself, addressing deficiency in PAH activity seen in phenylketonuria (PKU) patients.[1]
How Does Sapropterin Work as a PAH Cofactor?
PAH requires BH4 to hydroxylate phenylalanine, a reaction producing tyrosine, water, and oxidized biopterin (quinonoid dihydrobiopterin, qBH2). Sapropterin supplies exogenous BH4, enabling PAH function in patients with partial enzyme responsiveness. It binds to PAH's iron center, facilitating electron transfer for the hydroxylation.[2]
The process:
- BH4 reduces PAH's Fe3+ to Fe2+.
- Fe2+-BH4 complex attacks phenylalanine's aromatic ring.
- Reaction yields tyrosine and 4a-hydroxytetrahydrobiopterin, which spontaneously converts to qBH2.
BH4 Regeneration Cycle and Sapropterin's Indirect Regulation
Endogenous BH4 levels depend on de novo synthesis (from GTP via enzymes like GTP cyclohydrolase I) and recycling. Sapropterin boosts the pool available for PAH, but it also gets recycled:
- Dihydropteridine reductase (DHPR) reduces qBH2 back to BH4 using NADH.
- In PKU patients unresponsive to sapropterin, BH4 synthesis defects (e.g., in DHPR or pterin-4a-carbinolamine dehydratase) limit efficacy.
Sapropterin indirectly supports cofactor "creation" by preserving BH4 through this cycle, reducing oxidative loss, but it does not upregulate synthesis enzymes.[3]
Why Do Some PKU Patients Respond to Sapropterin?
About 20-30% of PKU patients have PAH mutations allowing BH4 responsiveness. Sapropterin stabilizes mutant PAH, increasing activity up to 30-fold in vitro by enhancing dimer-tetramer formation and catalytic efficiency. This chaperone-like effect lowers blood phenylalanine without dietary restriction.[4]
Limitations and What Happens Without It?
In non-responders, sapropterin fails because PAH is catalytically dead or BH4 recycling is impaired. Untreated PKU leads to hyperphenylalaninemia, neurotoxicity, and intellectual disability. Testing (BH4 loading test) predicts response by measuring phenylalanine drop post-dose.[1][5]
[1]: FDA Label for Kuvan (sapropterin)
[2]: Biochem J. PAH-BH4 mechanism
[3]: J Inherit Metab Dis. BH4 metabolism in PKU
[4]: Mol Genet Metab. Sapropterin chaperone effects
[5]: Orphanet J Rare Dis. BH4 responsiveness testing